Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089217 | 1.00 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL12411345 | 1.00 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL14256084 | 0.91 | ADORA3 (0.58) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| SCHEMBL12153356 | 0.90 | ADORA2A (0.57) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| Regadenoson Anhydrous SCHEMBL12958830 | 0.83 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| Regadenoson Anhydrous SCHEMBL14131217 | 0.83 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| Regadenoson Anhydrous SCHEMBL13462149 | 0.83 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| Regadenoson Anhydrous SCHEMBL21710782 | 0.83 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| Regadenoson Anhydrous SCHEMBL8925057 | 0.83 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1ADRA1A | |
| Regadenoson Anhydrous SCHEMBL6745611 | 0.83 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110166094-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | PGXHEALTH, L.L.C. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20090181920-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-07-16 | — | — | US | disclosed |
| US-20080312160-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-12-18 | — | — | US | disclosed |
| US-20080262001-A1 | a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester | ADENOSINE THERAPEUTICS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008124150-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | PDE4A, ADORA2A, PDE4B | ADORA2A 2/4885ADORA3 13/4885ADORA2B 11/4885 |
| US-20080262001-A1 | a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | ADORA2A, ADORA2B, PDE4A | ADORA2A 1/4885ADORA3 4/4885ADORA2B 2/4885 |
| US-20110166094-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA2B 4/4885 |
| US-20080312160-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | ADORA2A, ADORA3, GLUL | ADORA2A 1/4885ADORA3 2/4885ADORA2B 4/4885 |
| US-20090181920-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.